Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,214.24 +42.09 (+0.52%) Bitcoin USD
60,332.77 +1,447.39 (+2.46%) CMC Crypto 200
1,279.73 +2.75 (+0.22%)
BCRX Jan 2025 22.000 call
- GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 79,575 shares, and restricted stock units (RSUs) covering an aggregate of 42,400 shares, of BioCryst common stock. The options and RSUs were granted as of April 30, 2024, as inducements material to each employee entering into employmen
- Zacks
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
